Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$187.0 million.

  • Coherus Oncology's Cash from Financing Activities rose 101.20% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$281.6 million, marking a year-over-year decrease of 50.69%. This contributed to the annual value of -$187.0 million for FY2024, which is 368.64% down from last year.
  • According to the latest figures from FY2024, Coherus Oncology's Cash from Financing Activities is -$187.0 million, which was down 368.64% from $69.6 million recorded in FY2023.
  • Coherus Oncology's Cash from Financing Activities' 5-year high stood at $223.9 million during FY2020, with a 5-year trough of -$187.0 million in FY2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $54.3 million (2022), whereas its average is -$21.0 million.
  • Per our database at Business Quant, Coherus Oncology's Cash from Financing Activities skyrocketed by 150.58% in 2020 and then crashed by 368.64% in 2024.
  • Over the past 5 years, Coherus Oncology's Cash from Financing Activities (Yearly) stood at $223.9 million in 2020, then tumbled by 76.83% to $51.9 million in 2021, then grew by 4.72% to $54.3 million in 2022, then rose by 28.12% to $69.6 million in 2023, then tumbled by 368.64% to -$187.0 million in 2024.